Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries

Baseline rilpivirine drug resistance mutations (DRMs) are a risk factor for virological failure in patients treated with long-acting cabotegravir and rilpivirine (CAB/RPV LA). We investigated rilpivirine cross-resistance in treatment-naive and experienced patients in South Africa. One in 10 treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Steegen, Kim, Chandiwana, Nomathemba, Sokhela, Simiso, Venter, Willem D.F., Hans, Lucia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090297/
https://www.ncbi.nlm.nih.gov/pubmed/36779485
http://dx.doi.org/10.1097/QAD.0000000000003505
_version_ 1785022931260145664
author Steegen, Kim
Chandiwana, Nomathemba
Sokhela, Simiso
Venter, Willem D.F.
Hans, Lucia
author_facet Steegen, Kim
Chandiwana, Nomathemba
Sokhela, Simiso
Venter, Willem D.F.
Hans, Lucia
author_sort Steegen, Kim
collection PubMed
description Baseline rilpivirine drug resistance mutations (DRMs) are a risk factor for virological failure in patients treated with long-acting cabotegravir and rilpivirine (CAB/RPV LA). We investigated rilpivirine cross-resistance in treatment-naive and experienced patients in South Africa. One in 10 treatment-naive patients and 74.5% of patients failing treatment presented with rilpivirine DRMs. Our data suggest targeted genotyping may be required for patients initiating CAB/RPV LA, which significantly complicates the currently used public health approach.
format Online
Article
Text
id pubmed-10090297
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-100902972023-04-13 Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries Steegen, Kim Chandiwana, Nomathemba Sokhela, Simiso Venter, Willem D.F. Hans, Lucia AIDS Research Letter Baseline rilpivirine drug resistance mutations (DRMs) are a risk factor for virological failure in patients treated with long-acting cabotegravir and rilpivirine (CAB/RPV LA). We investigated rilpivirine cross-resistance in treatment-naive and experienced patients in South Africa. One in 10 treatment-naive patients and 74.5% of patients failing treatment presented with rilpivirine DRMs. Our data suggest targeted genotyping may be required for patients initiating CAB/RPV LA, which significantly complicates the currently used public health approach. Lippincott Williams & Wilkins 2023-05-01 2023-02-04 /pmc/articles/PMC10090297/ /pubmed/36779485 http://dx.doi.org/10.1097/QAD.0000000000003505 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Research Letter
Steegen, Kim
Chandiwana, Nomathemba
Sokhela, Simiso
Venter, Willem D.F.
Hans, Lucia
Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries
title Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries
title_full Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries
title_fullStr Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries
title_full_unstemmed Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries
title_short Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries
title_sort impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090297/
https://www.ncbi.nlm.nih.gov/pubmed/36779485
http://dx.doi.org/10.1097/QAD.0000000000003505
work_keys_str_mv AT steegenkim impactofrilpivirinecrossresistanceonlongactingcabotegravirrilpivirineinlowandmiddleincomecountries
AT chandiwananomathemba impactofrilpivirinecrossresistanceonlongactingcabotegravirrilpivirineinlowandmiddleincomecountries
AT sokhelasimiso impactofrilpivirinecrossresistanceonlongactingcabotegravirrilpivirineinlowandmiddleincomecountries
AT venterwillemdf impactofrilpivirinecrossresistanceonlongactingcabotegravirrilpivirineinlowandmiddleincomecountries
AT hanslucia impactofrilpivirinecrossresistanceonlongactingcabotegravirrilpivirineinlowandmiddleincomecountries

Ejemplares similares